Mutated KRAS induces upregulation of plasminogen activator inhibitor-1 (PAI-1) in pancreatic cancer cells which induces PSCs activation via LRP-1/ERK/c-JUN pathway to promote immunosuppression and fibrosis (82). This evidence concerns the gene SERPINE1 and pancreatic neoplasm.